Dupuytren's Contracture

1. Clinical Overview

Summary

Dupuytren's Disease is a benign, progressive fibroproliferative disorder of the palmar fascia characterized by pathological transformation of fibroblasts into contractile myofibroblasts. It initially presents as palmar nodules which coalesce into thick fibrous cords, causing fixed flexion contractures predominantly affecting the ring and little fingers. The condition exhibits strong genetic predisposition with autosomal dominant inheritance patterns, earning the colloquial name "Viking Disease" due to highest prevalence in populations of Northern European descent. [1,2]

The clinical threshold for surgical intervention is traditionally defined by a positive Hueston's Table Top Test (inability to place the palm flat on a surface), which typically correlates with metacarpophalangeal (MCP) joint contracture exceeding 30 degrees. Treatment options span a spectrum from minimally invasive Needle Aponeurotomy (NA) (higher recurrence, lower complication risk) to definitive Limited Fasciectomy (lower recurrence, higher surgical risk) and Dermofasciectomy for recurrent or aggressive disease. [3,4]

The most critical anatomical consideration is the Spiral Cord, a pathological structure that displaces the neurovascular bundle both centrally (toward the midline) and superficially (toward the skin), dramatically increasing the risk of iatrogenic digital nerve injury during surgical dissection. Understanding this three-dimensional anatomical distortion is fundamental to safe surgical practice. [5]

Key Facts

• Viking Disease: Prevalence reaches 30% in men over 60 in Scandinavia and Scotland, compared to 5-10% in general Northern European populations. [6]
• Dupuytren's Diathesis: Constellation of features predicting aggressive disease behavior: Young onset (less than 50 years), bilateral involvement, positive family history, and ectopic fibromatosis (Garrod's pads, Ledderhose disease, Peyronie's disease). Presence of diathesis increases lifetime recurrence risk to > 60%. [7]
• Pathological Signature: Transformation of normal fibroblasts to alpha-smooth muscle actin (α-SMA) expressing myofibroblasts, producing excessive Type III collagen. Shares molecular pathways with wound healing but lacks normal termination signals. [8]
• Anatomical Preservation: The disease selectively affects the palmar and digital fascia, sparing the flexor tendons, neurovascular bundles (though displacing them), and Cleland's ligament. The tendons themselves remain completely normal. [5]

Clinical Pearls

"Table Top Test": Ask the patient to place their hand flat on the examination table with fingers extended. Inability to achieve complete palm-table contact indicates MCP contracture ≥30 degrees and represents the traditional threshold for considering intervention. This simple clinical test has > 95% inter-observer reliability. [3]

"Painless Progression": Dupuytren's disease is characteristically painless in > 90% of cases. Presence of significant tenderness should prompt consideration of alternative diagnoses including trigger finger, ganglion cyst, palmar fasciitis, or early inflammatory arthropathy. Pain may occur during the early nodular proliferative phase but is transient. [9]

"The Spiral Cord Trap": The spiral cord is formed by pathological involvement of the spiral band, lateral digital sheet, Grayson's ligament, and pretendinous band. As this composite structure contracts, it creates a helical deformity that wraps around the neurovascular bundle, pulling the digital nerve up to 15mm centrally and 5mm superficially from its normal position. This anatomical distortion increases nerve injury risk 10-fold in revision surgery. [5,10]

"Recurrence vs Extension": True recurrence (return of disease at the previously treated site) must be distinguished from extension (new disease at previously uninvolved sites). Extension accounts for approximately 60% of perceived "recurrence" after fasciectomy. [11]

---

2. Epidemiology

Demographics

• Prevalence: Overall 3-6% in Caucasian populations; increases dramatically with age to 20-30% in men > 60 years. Rare before age 40. [6,12]
• Sex Distribution: Male:Female ratio approximately 6-9:1 for clinical disease. Female patients tend to present later (average 10 years older) but often with more aggressive digital involvement. [2]
• Age at Presentation: Peak incidence 60-70 years for men, 70-80 years for women. Onset before age 50 is a marker of aggressive diathesis. [7]
• Genetic Architecture: Autosomal dominant inheritance with variable penetrance (40-60% concordance in monozygotic twins). Genome-wide association studies have identified 26+ susceptibility loci including WNT signaling pathway genes. [13]
• Geographic Variation:
  • Highest: Scandinavia (30% men > 60), Iceland (28%), Scotland (25%)
  • Moderate: Northern Europe (10-15%), Australia (8-12%)
  • Low: Mediterranean populations (3-5%), Rare in Asian and African populations (less than 1%) [6]

Risk Factors

Established Risk Factors (Strong Evidence)

1. Genetic Predisposition: Family history in 68% of cases; 26 confirmed genetic loci including variants in WNT2, WNT4, and WNT7B genes affecting Wnt/β-catenin signaling. [13]
2. Northern European Ancestry: The "Viking Disease" moniker reflects documented migration patterns correlating with Norse settlements in Northern Europe, UK, and Iceland. [6]
3. Diabetes Mellitus: Present in 20-30% of Dupuytren's patients. Increases risk 3-4 fold but paradoxically associated with milder disease and slower progression. Proposed mechanism involves advanced glycation end-products (AGEs) affecting collagen cross-linking. [14]
4. Smoking: Dose-dependent relationship with pack-years. Increases risk 2-3 fold through microvascular ischemia promoting fibrosis and increasing myofibroblast activity. Risk persists 10+ years after cessation. [15]
5. Alcohol Consumption: Heavy alcohol use (> 35 units/week) increases risk 2-fold. Historical association with alcoholic liver cirrhosis partially confounded by shared genetic susceptibility. [16]

Associated Factors (Moderate Evidence)

6. Epilepsy/Anti-epileptics: Historic 40-50% prevalence in institutionalized epilepsy patients. Phenytoin and barbiturates implicated through fibroblast proliferation effects, though modern studies show lower association with current anti-epileptics. [2]
7. Manual Labor/Vibration: Controversial. Some occupational studies show increased prevalence in workers exposed to hand-held vibrating tools, but no definitive causal relationship established. Current evidence suggests genetic predisposition is primary factor. [17]
8. HIV/Antiretroviral Therapy: Emerging association with protease inhibitor therapy, possibly through dysregulation of TGF-β signaling. [2]

Protective Factors

• Asian and African Ancestry: Rare occurrence suggests genetic protection, though data limited by ascertainment bias.
• Female Sex: Lower prevalence and later onset, though more aggressive digital involvement when it occurs.

---

3. Pathophysiology

Molecular and Cellular Biology

Three-Phase Disease Model [8,18]

1. Proliferative Phase (Early Nodules)

• Activated myofibroblast proliferation
• High cell density with rich vascularization
• Expression of α-smooth muscle actin (α-SMA)
• Abundant Type III collagen production
• Active TGF-β1 and PDGF signaling
• May last months to years; nodules may be tender during this phase

2. Involutional Phase (Active Cord Formation)

• Myofibroblast alignment along lines of mechanical stress
• Progressive collagen cross-linking
• Reduction in cellularity and vascularity
• Maximum contractile force generation
• This phase drives the progressive contracture

3. Residual Phase (Established Contracture)

• Hypocellular, avascular scar tissue
• Dense Type I and III collagen matrix
• Minimal metabolic activity
• Fixed structural deformity
• Reduced response to collagenase treatment due to altered collagen composition

Key Molecular Pathways [8,13]

Wnt/β-Catenin Signaling

• Genome-wide association studies identify multiple WNT pathway genes
• β-catenin accumulation in myofibroblasts
• Drives proliferation and α-SMA expression
• Potential therapeutic target under investigation

TGF-β Superfamily

• TGF-β1 is master regulator of fibroblast-to-myofibroblast transformation
• Induces α-SMA expression and collagen synthesis
• Perpetuates autocrine stimulation loop
• Elevated in Dupuytren's tissue compared to normal fascia

Mechanical Tension

• Myofibroblasts respond to mechanical stress through mechanotransduction
• Explains distribution pattern along palmar aponeurosis stress lines
• Accounts for preferential ring and little finger involvement (highest mechanical load)

Anatomical Structures and Pathological Cords

Normal Palmar Fascial Anatomy

• Palmar Aponeurosis: Central triangular structure anchored to palmaris longus (when present)
• Pretendinous Bands: Four longitudinal bands aligned with each finger
• Spiral Band: Oblique structure from palmar fascia to lateral digital sheet
• Natatory Ligament: Connects pretendinous bands at webspaces
• Grayson's Ligament: Volar to neurovascular bundle
• Cleland's Ligament: Dorsal to neurovascular bundle - SPARED in Dupuytren's

Pathological Cord Classification [5,10]

Central Cord (Most Common - 85% of cases)

• Diseased pretendinous band
• Causes MCP joint contracture
• Neurovascular bundles remain in normal position
• Relatively safe surgical dissection
• Located in palm, superficial to flexor tendons

Spiral Cord (Most Dangerous - 30% of cases)

• Composite structure: spiral band + lateral digital sheet + Grayson's ligament + pretendinous band
• Causes PIP joint contracture (often severe)
• Three-dimensional neurovascular bundle displacement:
  • "Central: Up to 15mm toward midline"
  • "Superficial: Up to 5mm toward skin surface"
  • "Anterior: Around radial side of finger"
• Creates "spiral" wrapping around digital nerve
• Highest risk of iatrogenic nerve injury (10% primary surgery, 20% revision)
• Almost impossible to release percutaneously safely

Lateral Cord

• Diseased lateral digital sheet
• Causes PIP joint contracture
• Radial side of little finger, ulnar side of other digits
• Displaces neurovascular bundle centrally but less severely than spiral cord

Retrovascular Cord (Rare - less than 5%)

• Passes dorsal to neurovascular bundle
• Causes severe PIP contracture
• Difficult surgical access
• May require staged release

Natatory Cord

• Diseased natatory ligament
• Causes webspace contracture
• Results in thumb-index webspace narrowing or finger abduction contractures
• Impairs grip function

Isolated Digital Cord

• Confined to digit distal to MCP joint
• No palmar component
• More common in little finger
• May indicate aggressive diathesis if occurring in young patient

Ectopic Fibromatosis (Markers of Diathesis) [7]

Garrod's Pads (Knuckle Pads)

• Fibrotic nodules over dorsum of PIP joints
• Present in 40-50% of Dupuytren's patients with diathesis
• Histologically identical to palmar nodules
• May precede palmar disease

Ledderhose Disease (Plantar Fibromatosis)

• Nodular thickening of plantar fascia
• 10-20% of Dupuytren's patients
• Rarely causes contracture (foot anatomy prevents it)
• May cause walking discomfort

Peyronie's Disease (Penile Fibromatosis)

• Fibrotic plaques in dartos fascia of penis
• Causes penile curvature and erectile dysfunction
• 5-10% of Dupuytren's patients
• Shares identical molecular pathology

---

4. Clinical Presentation

Symptoms and Functional Impact

Early Disease

• Palmar Nodule: First manifestation in > 90% of cases. Firm, sometimes tender subcutaneous lump typically at the distal palmar crease aligned with ring or little finger. [9]
• Skin Pitting: Dimpling or puckering of overlying skin due to fibrous attachment to dermis (Skin involvement is pathognomonic). [2]
• Minimal Functional Loss: Patients often present because they noticed the lump, not due to disability.

Progressive Disease

• Flexion Contracture: Gradual inability to fully extend fingers. Patients report:
  • "I poke myself in the eye when washing my face"
  • "I can't get my hand flat in my pocket"
  • "I can't shake hands properly"
  • "I can't wear gloves"
• Webspace Narrowing: With natatory cord involvement, difficulty with grip and grasp.
• Pain: Unusual except during early proliferative nodule phase. Persistent pain suggests alternative diagnosis.

Advanced Disease

• Severe Contracture: MCP > 60 degrees, PIP > 40 degrees
• Hygiene Difficulties: Unable to clean palm, maceration in palm creases
• Functional Amputation: Finger so contracted it interferes with opposite fingers' function
• Skin Breakdown: Over PIP joints in severe contractures

Physical Examination Findings

Inspection

• Preferred Digits: Ring finger (60%) > Little finger (40%) > Middle finger (15%) > Index finger (5%) > Thumb (rare, less than 2%). [2]
• Bilateral Disease: Present in 40-60% at presentation, increases to 70% with longer follow-up. [7]
• Skin Changes:
  • Pitting/dimpling overlying nodules
  • Loss of normal skin creases
  • Longitudinal furrowing
  • In severe cases, skin atrophy and breakdown

Palpation

• Nodules: Firm, non-tender (except early proliferative phase), firmly attached to skin
• Cords: Palpable rope-like thickening from palm to digit
• Distinction from Tendons: Cords do not move with finger flexion (unlike flexor tendons)

Special Tests

Hueston's Table Top Test [3]

• Patient places hand palm-down on flat surface
• Attempts to fully extend all digits
• Positive Test: Inability to achieve complete palm-table contact
• Clinical Significance: Indicates MCP contracture ≥30°, traditional threshold for intervention
• Reliability: High inter-observer agreement (κ=0.92)

Passive Correction Test

• Distinguish:
  • "Contracture (soft tissue): Reducible with passive extension"
  • "Joint Stiffness: Not fully correctable due to capsular/collateral ligament changes"
• Clinical Significance: Determines realistic surgical goals. Longstanding PIP contractures > 40° often have irreversible capsular changes.

Hueston's Test for Active vs Passive Extension

• Compare active extension (patient effort) vs passive extension (examiner manipulates)
• Large discrepancy suggests concurrent extensor tendon dysfunction or central slip injury

Severity Grading [2]

Tubiana Classification (Most widely used)

• Stage 0: No contracture (nodules/cords only)
• Stage I: Total passive extension deficit (TPED) 0-45°
• Stage II: TPED 45-90°
• Stage III: TPED 90-135°
• Stage IV: TPED > 135°

TPED = MCP deficit + PIP deficit + DIP deficit (sum for each affected finger)

Associated Findings Suggesting Diathesis [7]

• Garrod's pads over PIP joints dorsally
• Bilateral disease in patient less than 50 years
• Plantar nodules (Ledderhose)
• Positive family history (> 1 first-degree relative)

---

5. Investigations

Clinical Diagnosis

Dupuytren's disease is a clinical diagnosis. No routine laboratory or imaging studies are required for typical presentations. [2]

Investigations - Indications

When to Consider Investigations

Ultrasound

• Indications:
  • Distinguish palmar mass from ganglion, lipoma, or giant cell tumor
  • Pre-operative mapping of neurovascular anatomy in revision cases
  • Research/teaching tool
• Findings: Hypoechoic nodules/cords with low vascularity (Doppler)
• Utility: Limited; palpation usually sufficient

MRI

• Indications:
  • Atypical presentation raising concern for soft tissue neoplasm
  • Complex revision surgery planning
• Findings: T1 iso/hypointense, T2 variable, minimal enhancement
• Utility: Rarely necessary; expensive and low yield

Genetic Testing

• Current Status: Research tool only
• Future Potential: Risk stratification for diathesis and recurrence prediction
• Not Indicated: For routine clinical management

Pre-operative Assessment

Allen's Test (Essential before any cord release procedure)

• Assesses adequacy of collateral circulation (ulnar vs radial artery dominance)
• Technique:
  1. Patient makes fist; examiner occludes radial and ulnar arteries
  2. Patient opens hand (should be pale)
  3. Release ulnar artery; observe capillary refill to radial side
  4. Repeat releasing radial artery
• Positive Test: Capillary refill less than 5 seconds indicates adequate collateral flow
• Significance: Ensures digital perfusion maintained if one digital artery injured during surgery

Photography

• Document pre-operative contracture severity
• Standardized hand positioning for outcomes research

Informed Consent Discussion Points [4]

• Recurrence/extension risk (15-50% depending on procedure and diathesis)
• Nerve injury risk (2-5% primary, 10-20% revision)
• CRPS/Flare reaction risk (5-10%)
• Wound healing complications (10-15%)
• Need for potential revision surgery (30-40% lifetime risk with diathesis)

---

6. Differential Diagnosis

Key Differential Diagnoses

Trigger Finger (Stenosing Tenosynovitis)

• Distinguish: Painful clicking/locking during active flexion-extension; tender over A1 pulley; no palpable cord; no skin pitting
• May Coexist: 10-15% of Dupuytren's patients also have trigger finger

Camptodactyly

• Distinguish: Congenital or adolescent-onset PIP flexion contracture; no palmar pathology; little finger typically affected; positive family history
• Key Difference: No palmar nodules/cords; present from childhood

Diabetic Cheiroarthropathy

• Distinguish: Progressive stiffness all joints (not just flexion contracture); waxy skin; positive "prayer sign" (unable to approximate palms); associated with poor diabetic control
• May Coexist: Diabetes is risk factor for both conditions

Ulnar Tunnel Syndrome (Guyon's Canal)

• Distinguish: Hypothenar tenderness; sensory changes ulnar 1.5 digits; weakness of interossei; Tinel's over Guyon's canal
• Anatomy: Dupuytren's cords may compress ulnar nerve at Guyon's canal (rare)

Volkmann's Contracture

• Distinguish: History of trauma/compartment syndrome; intrinsic-plus deformity; muscle necrosis sequelae
• Key Difference: Acute traumatic onset; involves muscles not fascia

Palmar Fibromatosis vs Neoplasm

• Giant Cell Tumor of Tendon Sheath: Mobile, lobulated mass; not fixed to skin
• Soft Tissue Sarcoma: Rapid growth; pain; systemic symptoms; MRI shows heterogeneous mass with enhancement
• Ganglion Cyst: Transilluminates; fluctuant; may communicate with joint

---

7. Management Algorithm

                  DUPUYTREN'S DISEASE PRESENTATION
                             ↓
          ┌──────────────────┴──────────────────┐
          │                                     │
    NODULES ONLY                      CONTRACTURE PRESENT
   (No Extension                    (Positive Table Top Test
     Deficit)                        or TPED > 30 degrees)
          ↓                                     ↓
     OBSERVATION                    ┌───────────┴────────────┐
  (95% stable or                    │                        │
   slow progression)         PATIENT SELECTION        ASSESS SEVERITY
   ├─ Reassure                      ↓                        ↓
   ├─ Annual review            CONSIDER:                TUBIANA STAGE
   ├─ Monitor photographs    • Age/Comorbidities         & DIATHESIS
   └─ Advise re threshold    • Hand dominance                ↓
      for intervention       • Occupational needs    ┌───────┴────────┐
                            • Patient preference     │                │
                            • Surgical fitness    STAGE I-II       STAGE III-IV
                                    ↓             (TPED less than 90°)      (TPED > 90°)
                            ┌───────┴────────┐          ↓              ↓
                            │                │     ┌────┴─────┐   FASCIECTOMY
                     LOW RISK           HIGH RISK  │          │   (Open Surgery)
                   (Elderly, Single    (Young, Bilateral,  CHOOSE:    ± Dermofasciectomy
                    digit, No          Diathesis,          │          if recurrent
                    diathesis)         High demand)        │          or aggressive
                         ↓                    ↓            │          diathesis
              ┌──────────┴────────┐    FASCIECTOMY    NEEDLE        │
              │                   │         OR        APONEUROTOMY   │
         NEEDLE               COLLAGENASE  DERMOFASCIECTOMY  OR      │
       APONEUROTOMY          (if available   (Definitive)   COLLAGENASE
       (Percutaneous)         in region)                    (if available)
              │                   │                             ↓
              └─────────┬─────────┘                    POST-OPERATIVE
                        ↓                               ├─ Night splint 3-6mo
              COUNSEL REGARDING:                        ├─ Hand therapy
              • 50-85% recurrence 3-5yr                 ├─ Expect 6-12wk recovery
              • Quick recovery (days)                   └─ Monitor for complications
              • Repeatable procedure
              • Nerve injury risk 1-3%

---

8. Management: Non-Operative

Observation (Nodular Phase or Mild Contracture)

Indications [2,3]

• No Contracture: Palpable nodules/cords without extension deficit (Tubiana Stage 0)
• Minimal Contracture: TPED less than 30° with negative table top test and no functional limitation
• Patient Preference: Informed patient chooses to defer intervention

Natural History Data

• Progression: Variable and unpredictable
  • 30-40% remain stable for years
  • 30-40% progress slowly over decades
  • 20-30% progress rapidly (especially with diathesis)
• Spontaneous Regression: Extremely rare (less than 1%), typically only early nodules
• Time to Intervention: Average 4-7 years from first nodule to surgical threshold in progressive disease [2]

Observation Protocol

• Baseline Photography: Document initial presentation
• Annual Review: Clinical examination, repeat photography
• Patient Education:
  • Natural history and expected progression
  • Warning signs requiring earlier review (rapid progression)
  • Threshold for intervention (table top test)
  • Recurrence/extension risk regardless of treatment chosen
• "Watchful Waiting" Not "Do Nothing": Active surveillance with clear intervention thresholds

Ineffective Interventions (Historical Interest Only)

The following have been tried historically but lack efficacy evidence:

• Splinting/Stretching: No evidence for prevention or slowing progression; may increase inflammation
• Radiotherapy: Used in Germany/Netherlands; controversial efficacy; concerns about secondary malignancy
• Intralesional Corticosteroids: No proven benefit
• Topical/Oral Medications: Vitamin E, tamoxifen, colchicine - all ineffective
• Shockwave Therapy: Insufficient evidence

---

9. Management: Procedures

1. Needle Aponeurotomy (NA) / Percutaneous Fasciotomy

Technique [19]

• Anesthesia: Local anesthetic (1% lidocaine without epinephrine) injected around cord
• Instrument: 25G or 23G hypodermic needle used as micro-scalpel
• Method:
  • Multiple percutaneous punctures along cord
  • Needle bevel used to "saw" through cord fibers
  • Avoid neurovascular bundle by staying superficial and volar
  • Serial release until cord weakens
  • Passive extension force applied to rupture remaining fibers
• Closure: No sutures; adhesive dressings; immediate mobilization

Indications

• Ideal Candidates:
  • Elderly patients (> 75 years)
  • Significant comorbidities precluding general anesthesia
  • Single-digit MCP contracture (less than 60°)
  • Patient unwilling to undergo formal surgery
  • Patient accepts high recurrence risk for quick recovery
• Acceptable: Well-informed younger patients choosing this for lifestyle reasons

Contraindications

• Absolute:
  • Severe PIP contracture (> 40°) - spiral cord with displaced neurovascular bundle
  • Recurrent disease in previously operated field (scarring distorts anatomy)
• Relative:
  • Young age with diathesis (will recur rapidly)
  • Anticoagulation (relative; increased hematoma risk)

Outcomes [19,20]

• Immediate Correction: Excellent (80-95% achieve full or near-full MCP extension)
• Recurrence:
  • 1 year: 15-30%
  • 3 years: 50-65%
  • 5 years: 85% (Van Rijssen landmark RCT) [19]
• Extension vs Recurrence: Difficulty distinguishing; likely both contribute
• Patient Satisfaction: High despite recurrence due to minimal recovery burden

Complications [19,20]

• Nerve Injury: 1-3% (most are transient neurapraxia; permanent injury less than 0.5%)
• Tendon Rupture: Rare (less than 1%), usually FDS of little finger
• Skin Tear: 10-20%; usually minor; heal by secondary intention
• Hematoma: 5-10%; rarely requires intervention
• Infection: less than 1%
• CRPS: less than 2% (lower than open surgery)

Post-Procedure Protocol

• Immediate: Active motion encouraged immediately
• Splinting: Night extension splint for 3-6 months (compliance variable; benefit unproven)
• Return to Activities: Days to 1-2 weeks
• Follow-up: 2 weeks, 3 months, then annually to detect recurrence

2. Collagenase Injection (Xiaflex / Xiapex)

Background

• Mechanism: Clostridium histolyticum-derived bacterial collagenase that enzymatically cleaves Type I and III collagen
• Regulatory Status: FDA-approved in USA (2010); withdrawn from European market (2020) for commercial reasons, NOT safety/efficacy concerns
• Current Availability: Available in USA, Australia; not available in UK/Europe

Technique [4]

• Day 1 - Injection:
  • Inject 0.58mg collagenase directly into palpable cord
  • Local anesthetic NOT used (may dilute enzyme)
  • MCP cords: Single injection
  • PIP cords: May require injection at multiple sites
  • Hand wrapped; patient sent home
• Day 2-3 - Manipulation:
  • Digital block performed
  • Passive extension force applied to rupture enzymatically weakened cord
  • Audible "snap" often heard/felt
  • Extension splint applied

Indications

• FDA-approved for isolated MCP or PIP contracture with palpable cord
• Older patients desiring minimally invasive option
• Suitable for patients unable/unwilling to undergo surgery

Contraindications

• Absolute:
  • Allergy to collagenase or previous anaphylaxis
  • Cord involved at PIP joint with concurrent other local pathology
• Relative:
  • Anticoagulation (higher bleeding risk)
  • Multiple cord involvement (requires staged treatments)

Outcomes [4]

• Correction: 75-85% achieve clinical success (≤5° residual contracture)
• Recurrence: Similar to needle aponeurotomy (50-60% at 5 years)
• Cost-Effectiveness: Significantly more expensive than NA or fasciectomy in most healthcare systems

Complications [4]

• Common (> 10%): Swelling, bruising, pain, skin splitting, pruritus
• Significant:
  • Tendon rupture: 0.3-0.5% (particularly FDS little finger)
  • Pulley rupture: Rare; causes bowstringing
  • CRPS: 2-5%
  • Nerve injury: less than 1%
• Rare: Anaphylaxis (less than 0.1%; usually in patients receiving multiple courses)

Current Clinical Role

• Effective alternative where available
• Higher cost limits widespread adoption
• Similar recurrence to NA but avoids needle "sawing" technique
• May be preferred by some patients despite cost

3. Limited Fasciectomy - The Gold Standard

Technique [3,5,10]

• Anesthesia: General, regional block (axillary/supraclavicular), or wide-awake local anesthesia no tourniquet (WALANT)
• Incision:
  • Bruner Zig-Zag: Multiple transverse incisions connected by diagonal segments (preferred for digital cords)
  • Longitudinal: Avoided (contracts and causes bow-stringing)
  • Z-plasty: Incorporated for skin lengthening when skin involved
• Dissection:
  • Identify and protect neurovascular bundles throughout
  • Carefully dissect pathological fascia from:
    • Overlying skin (often adherent)
    • Underlying flexor tendons (normal; preserve)
    • Neurovascular bundles (displaced; high risk)
  • Complete excision of diseased fascia (nodules and cords)
  • Key Principle: Remove all visible diseased tissue without devascularizing skin or injuring neurovascular structures
• Reconstruction:
  • Z-plasty for skin lengthening (often required for severe contractures)
  • Primary closure when possible
  • Full-thickness skin graft if skin deficit (transitions to dermofasciectomy)
• Closure: Absorbable subcuticular sutures; soft dressing; dorsal extension splint

Indications [3]

• Primary Treatment:
  • MCP contracture > 30° (positive table top test)
  • Any PIP contracture causing functional limitation
  • Younger patients (less than 70) with good surgical fitness
  • Patients desiring definitive treatment with lowest recurrence
• Patient Selection Favoring Fasciectomy:
  • Diathesis features (aggressive disease warrants aggressive treatment)
  • Bilateral disease (can stage procedures)
  • High functional demands (occupation/hobbies)

Outcomes [3,10,19]

• Immediate Correction:
  • MCP contractures: 90-100% correction achievable
  • PIP contractures: 60-80% correction (limited by joint capsular changes if longstanding)
• Recurrence (Van Rijssen 5-year RCT) [19]:
  • True recurrence at treated site: 15-21%
  • Extension to new sites: 20-30%
  • Combined recurrence/extension: 30-40% at 5 years
  • Diathesis patients: 60-70% lifetime recurrence/extension risk
• Functional Outcomes:
  • 85-90% patient satisfaction at 5 years
  • DASH scores improve by average 15-20 points
  • Grip strength returns to 80-90% contralateral by 6 months

Complications [3,10]

• Digital Nerve Injury: 2-5% (most common serious complication)
  • Neurapraxia (transient): 2-3%
  • Permanent sensory loss: 1-2%
  • Complete division: less than 1% (requires immediate repair)
  • Risk Factors: Spiral cord, PIP involvement, revision surgery (10-20%), surgeon inexperience
• Digital Artery Injury: 1-2%
  • Single artery: Usually tolerated if collateral circulation adequate (Allen's test)
  • Both arteries: Digital necrosis/amputation (less than 0.1%)
• Hematoma: 5-10%
  • Most resolve spontaneously
  • Large hematomas: May require evacuation to prevent infection/CRPS
• Infection: 2-5% (higher than most clean surgery due to hand bacterial colonization)
• Wound Dehiscence: 5-15% (especially with tension or Z-plasty)
  • Managed with dressing changes; healing by secondary intention
• Complex Regional Pain Syndrome (CRPS) / "Flare Reaction": 5-10% [21]
  • Hand becomes swollen, red, stiff, painful, hypersensitive
  • Early aggressive hand therapy + pain management critical
  • Most resolve 3-6 months but can cause permanent stiffness
  • Risk factors: Female sex, previous CRPS, severe initial contracture
• Stiffness: 10-20% experience some degree of permanent stiffness
• Recurrence/Extension: 30-40% at 5 years (see above)

Post-Operative Protocol

• Immediate (0-2 weeks):
  • Dorsal extension splint (day and night)
  • Elevate hand to minimize edema
  • Gentle active finger flexion exercises (avoid passive stretching early)
• 2-6 Weeks:
  • Night splinting only
  • Formal hand therapy: Active and gentle passive ROM exercises
  • Scar massage
  • Gradual return to activities of daily living
• 6 Weeks - 3 Months:
  • Continue night splint (3-6 months total; compliance variable)
  • Progressive strengthening
  • Return to unrestricted activities by 8-12 weeks
• Long-Term:
  • Annual surveillance for recurrence/extension
  • Patient educated on early signs of recurrence

4. Dermofasciectomy - The "Firebreak"

Rationale [22]

• Hueston's "Firebreak" Theory: Myofibroblast activity requires intact dermis-fascia interaction. Replacing involved skin with full-thickness skin graft (FTSG) disrupts this signaling, reducing recurrence.
• Evidence: Recurrence rates 10-15% at 5 years (approximately half that of standard fasciectomy in high-risk patients). [22]

Technique [22]

• Excision: Remove diseased fascia AND overlying involved skin (identified by pitting/adherence)
• Defect: Creates skin deficit requiring reconstruction
• Skin Graft:
  • FTSG preferred (medial arm, groin, hypothenar eminence)
  • Thick split-thickness graft acceptable alternative
  • Secured with tie-over bolster dressing
• Immobilization: 5-7 days for graft take, then gradual mobilization

Indications [22]

• Recurrent Disease: After previous fasciectomy (most common indication)
• Aggressive Diathesis: Young patient (less than 50) with bilateral disease and ectopic features undergoing primary surgery
• Severe Skin Involvement: Skin so contracted/atrophic that primary closure impossible

Outcomes [22]

• Recurrence: 10-15% at 5 years (superior to fasciectomy in high-risk patients)
• Function: Similar ROM outcomes to fasciectomy once healed
• Cosmesis: Visible graft; usually acceptable to patients who have already failed previous treatment

Complications

• All Fasciectomy Complications (nerve injury, etc.) PLUS:
• Graft Failure: 5-10% (partial or complete)
• Prolonged Healing: 3-4 weeks for graft maturation (vs 2-3 weeks for fasciectomy)
• Hyperpigmentation: Graft may darken (especially in patients with darker skin)
• Donor Site Morbidity: Scar at graft harvest site

5. Amputation

Indications

• Severe Neglected Contracture: Finger fixed at > 90° MCP and PIP, causing hygiene problems or interfering with other fingers
• Failed Multiple Revisions: Recurrent disease with severe scarring making further surgery impossible
• Patient Preference: After informed discussion; some patients prefer amputation to multiple failed revisions

Technique

• Usually ray amputation (remove entire metacarpal) for little finger to narrow hand
• Single digit amputation for other fingers

Outcomes

• High patient satisfaction when appropriate indication
• Excellent function for little finger amputation
• Avoids recurrent surgery cycle

---

10. Prognosis and Long-Term Outcomes

Disease-Specific Prognostic Factors

Dupuytren's Diathesis (Strongest Predictor) [7]

• Age less than 50 at onset: Hazard ratio 3.2 for recurrence
• Bilateral disease: HR 2.1
• Ectopic disease (Garrod's/Ledderhose/Peyronie's): HR 2.8
• Positive family history: HR 1.9
• All 4 factors present: > 70% recurrence/extension by 5 years regardless of treatment

Anatomical Factors

• PIP Involvement: 2-3x recurrence risk vs MCP alone
• Little Finger: Higher recurrence than ring/middle
• Radial Digits (index/thumb): Rare but very aggressive when involved

Treatment Selection Impact

• Fasciectomy: 15-21% true recurrence at 5 years [19]
• Needle Aponeurotomy: 85% recurrence at 5 years [19]
• Dermofasciectomy: 10-15% recurrence at 5 years [22]
• No Treatment: Variable progression; 30-40% remain stable

Patient Counseling Points

Realistic Expectations

• "Cure" is Not Possible: Genetic disease; fasciectomy removes tissue manifestation but doesn't change underlying predisposition
• Extension vs Recurrence: New disease at previously uninvolved sites accounts for > 50% of "recurrence"
• Revision Surgery: 30-40% of diathesis patients require revision within 10 years
• Risk-Benefit Trade-off: Needle aponeurotomy (low risk, high recurrence) vs fasciectomy (higher risk, lower recurrence)

Functional Outcomes

• MCP Contractures: Excellent correction expected (> 90%)
• PIP Contractures:
  • less than 40° pre-op: 80% achieve full correction
  • 40-60° pre-op: 50-60% achieve functional (≤20° residual)

  • 60° pre-op: Often cannot achieve full correction due to joint capsular changes

• Stiffness: Temporary stiffness is expected; permanent stiffness in 10-20%

When to Refer to Specialist Hand Surgeon

Primary Care Indications for Referral

• Positive table top test (contracture > 30°)
• Any PIP contracture causing functional limitation
• Young patient with diathesis for counseling
• Rapid progression (> 10° increase in 6 months)
• Patient requesting treatment for nodular disease

Complexity Factors Requiring Experienced Hand Surgeon

• PIP contracture > 40° (spiral cord likely)
• Revision surgery (10x nerve injury risk)
• Multiple digits requiring simultaneous release
• Recurrent disease with diathesis (consider dermofasciectomy)

---

11. Special Considerations

Revision Surgery [10]

Anatomical Challenges

• Scar Tissue: Obliterates normal tissue planes
• Neurovascular Displacement: Even more unpredictable than primary surgery
• Skin Deficiency: Previous Z-plasties consume available skin
• Nerve Injury Risk: Increases 10-fold (10-20% vs 2% primary) [10]

Technical Approaches

• Extensive Exposure: Wider incisions to clearly identify anatomy
• Dermofasciectomy Often Required: Both to reduce recurrence and manage skin deficit
• Consider Amputation: Discuss as alternative in multiply-recurrent little finger disease

Dupuytren's in Special Populations

Women

• Later onset: Average 10 years older than men
• Higher PIP involvement: More aggressive digital disease when it occurs
• Higher CRPS risk: 2-3x baseline risk

Diabetic Patients [14]

• Milder phenotype: Slower progression, less severe contractures
• Higher wound complications: 15-20% vs 5-10% non-diabetic
• Poorer PIP outcomes: Possibly related to diabetic cheiroarthropathy overlap

Young Patients (less than 40 years)

• Aggressive diathesis assumed until proven otherwise
• Counsel about recurrence: Lifetime recurrence/extension > 70%
• Consider dermofasciectomy even for primary surgery in severe cases
• Genetic counseling: Discuss inheritance for family planning

---

12. Patient Explanation (Layperson Summary)

What is it?

Dupuytren's disease is a genetic condition where the layer of tissue under the skin in your palm gradually thickens and forms tight cords. These cords are like internal scars that slowly pull your fingers down toward your palm so you can't straighten them completely. It's nicknamed "Viking Disease" because it's most common in people with Northern European ancestry, particularly Scandinavian heritage.

Why did I get it?

It runs in families—about 2 out of 3 people with Dupuytren's have a relative with the same condition. Certain factors make it more common, including smoking, diabetes, and heavy alcohol use, but the main cause is genetic. You didn't do anything to cause it, and you couldn't have prevented it.

Do I need surgery?

Not necessarily, especially in the early stages. If you only have lumps (nodules) without finger bending, we usually just watch it because it may not progress for years, or ever. We typically recommend treatment when you can't place your hand flat on a table anymore (the "table top test"), which usually means your finger is bent more than 30 degrees. At that point, it's starting to interfere with daily activities like shaking hands, wearing gloves, or washing your face.

What are my treatment options?

1. The Needle Procedure (Needle Aponeurotomy)

• We numb your hand and use a needle to cut the cord under the skin
• Pros: Done in clinic; you're awake; no stitches; back to normal activities in days
• Cons: It comes back in most people within 3-5 years (you may need it repeated)
• Best for: Older patients, those who want quick recovery, or those not fit for surgery

2. Open Surgery (Fasciectomy)

• We make a zig-zag cut in your palm and finger, remove the diseased tissue, and stitch it closed
• Pros: Lasts much longer (most people stay better for 10+ years); more complete correction
• Cons: 6-12 week recovery; small risk of nerve damage (2-5%); can develop hand stiffness
• Best for: Younger patients, severe contractures, those wanting definitive treatment

3. Surgery with Skin Graft (Dermofasciectomy)

• We remove the diseased tissue AND the overlying skin, then cover the area with a skin graft from another part of your body
• Best for: When disease has come back after previous surgery; very aggressive disease
• Pros: Lowest recurrence rate (about 10% come back)
• Cons: Longer healing (3-4 weeks), visible graft, scar at donor site

What are the risks?

The main risks of surgery are:

• Nerve damage (2-5%): Could cause numbness in part of your finger, usually temporary
• Bleeding/bruising: Common, usually settles on its own
• Stiffness (10-20%): Hand therapy helps prevent this
• Complex Regional Pain Syndrome (CRPS) (5-10%): Hand becomes painful, swollen, and stiff; most cases improve with treatment over 3-6 months
• Recurrence (15-40% depending on procedure): The disease is in your genes, so it can come back even after surgery

Will it come back?

Probably, eventually. This is a genetic condition, not a one-time problem. Surgery removes the tissue that's already diseased, but it doesn't change your genes. About 1 in 3 people need another procedure within 10 years. Certain features (called "diathesis") predict higher recurrence risk:

• Young age when it started (under 50)
• Lumps on both hands
• Family members with severe disease
• Lumps on your knuckles, feet, or other areas

What happens if I don't treat it?

It varies. About 1 in 3 people stay stable for years without much change. Others progress slowly over decades. Some progress quickly. There's no reliable way to predict. We'll monitor you regularly with photographs and measurements. You can always choose treatment later if it worsens. Waiting doesn't make surgery riskier unless you develop very severe contractures (> 90 degrees).

How do I decide?

Consider:

• How much does it bother you functionally?
• What's your general health (fit for surgery)?
• What's your occupation and hand use requirements?
• Are you willing to accept recurrence for quicker recovery (needle), or surgery with longer recovery for more durable result?

Most importantly, this is YOUR hand and YOUR decision. We're here to give you the information and support you in whatever choice makes sense for your life.

---

13. References

1. Bayat A, McGrouther DA. Management of Dupuytren's disease--clear advice for an elusive condition. Ann R Coll Surg Engl. 2006;88(1):3-8. doi:10.1308/003588406X83104

2. Trojian TH, Chu SM. Dupuytren's disease: diagnosis and treatment. Am Fam Physician. 2007;76(1):86-89. PMID: 17668845

3. Becker GW, Davis TR. The outcome of surgical treatments for primary Dupuytren's disease--a systematic review. J Hand Surg Eur Vol. 2010;35(8):623-626. doi:10.1177/1753193410373845

4. Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg Am. 2013;38(1):12-22. doi:10.1016/j.jhsa.2012.09.028

5. McFarlane RM. The current status of Dupuytren's disease. J Hand Ther. 1995;8(3):181-184. doi:10.1016/s0894-1130(12)80316-6

6. Lanting R, Broekstra DC, Werker PM, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg. 2014;133(3):593-603. doi:10.1097/01.prs.0000438455.37604.0f

7. Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009;4(3):256-269. doi:10.1007/s11552-008-9160-9

8. Townley WA, Baker R, Sheppard N, Grobbelaar AO. Dupuytren's contracture unfolded. BMJ. 2006;332(7538):397-400. doi:10.1136/bmj.332.7538.397

9. Shaw RB Jr, Chong AK, Zhang A, Hentz VR, Chang J. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg. 2007;120(3):44e-54e. doi:10.1097/01.prs.0000278455.63546.03

10. Strickland JW, Bassett RL. The isolated digital cord in Dupuytren's contracture: anatomy and clinical significance. J Hand Surg Am. 1985;10(1):118-124. doi:10.1016/s0363-5023(85)80258-0

11. Werker PM, Pess GM, van Rijssen AL, Denkler K. Aggression factors in Dupuytren's disease: the influence on recurrence. J Hand Surg Br. 2009;34(2):196-200. doi:10.1016/j.jhsb.2008.11.019

12. Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol. 2000;53(3):291-296. doi:10.1016/s0895-4356(99)00145-6

13. Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren's disease. N Engl J Med. 2011;365(4):307-317. doi:10.1056/NEJMoa1101029

14. Arkkila PE, Kantola IM, Viikari JS, Rönnemaa T. Dupuytren's disease in type 1 diabetic patients: a five-year prospective study. Clin Exp Rheumatol. 1996;14(1):59-65. PMID: 8697657

15. Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br. 1997;79(2):206-210. doi:10.1302/0301-620x.79b2.7134

16. Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br. 1984;66(3):322-325. doi:10.1302/0301-620X.66B3.6725338

17. Palmer KT, D'Angelo S, Syddall H, et al. Dupuytren's contracture and occupational exposure to hand-transmitted vibration. Occup Environ Med. 2014;71(4):241-245. doi:10.1136/oemed-2013-101904

18. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-363. doi:10.1038/nrm809

19. van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012;129(2):469-477. doi:10.1097/PRS.0b013e31823aea95

20. Skov ST, Bisgaard T, Søndergaard P, et al. Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. J Hand Surg Am. 2017;42(5):321-328. doi:10.1016/j.jhsa.2017.03.003

21. Vranceanu AM, Barsky A, Ring D. Psychosocial aspects of disabling musculoskeletal pain. J Bone Joint Surg Am. 2009;91(8):2014-2018. doi:10.2106/JBJS.H.01512

22. Ullah AS, Dias JJ, Bhowal B. Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture?: a prospective trial. J Bone Joint Surg Br. 2009;91(3):374-378. doi:10.1302/0301-620X.91B3.21054

---

14. Examination Focus (Viva Vault)

Q1: What is the Spiral Cord and why is it clinically significant?

Model Answer: The spiral cord is the most dangerous pathological structure in Dupuytren's disease. It is a composite cord formed by the coalescence of four anatomical structures: the spiral band (oblique fibers from palm to lateral digital sheet), lateral digital sheet, Grayson's ligament (volar to neurovascular bundle), and the pretendinous band.

Clinical Significance: As this composite structure contracts, it creates a three-dimensional helical deformity that displaces the neurovascular bundle in three directions:

1. Centrally (toward midline): Up to 15mm
2. Superficially (toward skin): Up to 5mm
3. Anteriorly (wraps around radial aspect of finger)

This displacement puts the digital nerve at extreme risk during surgical dissection because it is NOT in its expected anatomical position. The nerve may be encountered unexpectedly superficial and central to where the surgeon expects. This accounts for the 10-20% nerve injury rate in revision surgery involving spiral cords, compared to 2% for simple central cords.

Anatomical Principle: The spiral cord typically causes PIP joint contracture (not MCP), and most commonly affects the little and ring fingers.

---

Q2: Which anatomical structure is consistently spared in Dupuytren's disease and why is this clinically useful?

Model Answer: Cleland's Ligament is consistently spared in Dupuytren's disease.

Anatomy: Cleland's ligament runs from the phalanx on the dorsolateral aspect of the digit, passing dorsal to the neurovascular bundle, and inserting into the lateral aspect of the extensor mechanism. Its function is to stabilize the skin during finger flexion.

Why Spared: The pathological process of Dupuytren's disease selectively affects volar structures (palmar and digital fascia, Grayson's ligament, natatory ligament, spiral band) but does not involve dorsal structures.

Clinical Utility: Cleland's ligament serves as a reliable anatomical landmark during surgery:

• Everything volar to Cleland's ligament is potentially diseased and involved
• Everything dorsal to Cleland's ligament is safe and disease-free
• It helps the surgeon maintain proper dissection plane
• It defines the dorsal limit of safe excision

In contrast, Grayson's ligament (which runs volar to the neurovascular bundle) is frequently involved in Dupuytren's disease and is a component of the spiral cord.

---

Q3: Define Dupuytren's Diathesis and explain its prognostic significance.

Model Answer: Dupuytren's Diathesis is a constellation of features that predict aggressive disease behavior and high recurrence risk. Originally described by Hueston, it includes:

The Four Cardinal Features:

1. Young Age of Onset: less than 50 years (particularly aggressive if less than 40)
2. Bilateral Disease: Involvement of both hands
3. Positive Family History: Affected first-degree relatives
4. Ectopic Fibromatosis:
   • Garrod's pads (knuckle pads over dorsal PIP joints)
   • Ledderhose disease (plantar fibromatosis)
   • Peyronie's disease (penile fibromatosis)

Prognostic Significance:

• Recurrence Risk: Presence of diathesis increases lifetime recurrence/extension risk to > 70% regardless of treatment modality
  • 0-1 factors: ~20% recurrence at 5 years
  • 2-3 factors: ~50% recurrence at 5 years
  • "All 4 factors: > 70% recurrence at 5 years"

Clinical Implications:

1. Patient Counseling: Must discuss realistic expectations about recurrence
2. Treatment Selection:
   • Consider dermofasciectomy even for primary surgery in severe diathesis
   • Needle aponeurotomy likely inappropriate (will recur rapidly)
3. Surveillance: Requires closer long-term follow-up
4. Genetic Counseling: 40-60% offspring concordance; discuss for family planning

Biological Basis: Diathesis likely represents more aggressive genetic susceptibility with dysregulated Wnt/β-catenin signaling and TGF-β pathways, leading to sustained myofibroblast activity.

---

Q4: Explain the rationale for dermofasciectomy and the "Firebreak" theory.

Model Answer: Dermofasciectomy involves excision of diseased palmar/digital fascia and the overlying involved skin, with reconstruction using a full-thickness skin graft (FTSG).

Hueston's "Firebreak" Theory: The pathological process of Dupuytren's disease requires intact dermis-fascia interaction for myofibroblast activity. Specifically:

1. Myofibroblasts in the superficial fascia receive proliferative signals from the overlying dermis
2. These signals involve growth factors (TGF-β, PDGF) and mechanical tension
3. The dermis-fascia interface is essential for sustained disease activity

By replacing the diseased dermis with a skin graft, you disrupt this pathological signaling:

• The graft dermis lacks the disease-specific cellular architecture
• Interrupts the growth factor signaling cascade
• Acts as a "firebreak" preventing disease recurrence at that site

Evidence:

• Recurrence rates with dermofasciectomy: 10-15% at 5 years
• Standard fasciectomy in high-risk patients: 40-60% recurrence at 5 years
• Ullah et al. (2009) prospective trial confirmed significantly reduced recurrence [Reference 22]

Indications:

1. Recurrent disease after previous fasciectomy (most common)
2. Primary surgery in severe diathesis (young, bilateral, ectopic disease)
3. Severe skin involvement where primary closure impossible

Trade-offs:

• Longer healing time (3-4 weeks)
• Donor site morbidity
• Visible graft with potential hyperpigmentation
• BUT: Substantially reduced recurrence in appropriate patients makes it worthwhile

---

Q5: Compare and contrast needle aponeurotomy versus limited fasciectomy.

Model Answer:

Key Decision Factors:

1. Patient Age/Fitness: Elderly/comorbid favor NA; young/fit favor fasciectomy
2. Contracture Severity: MCP only - either; severe PIP - fasciectomy only
3. Patient Priorities: Quick recovery vs durability
4. Diathesis: If present, NA will recur very rapidly; fasciectomy preferred

Van Rijssen Landmark RCT (2012) [Reference 19]:

• Randomized 110 patients to NA vs fasciectomy
• 5-year results: NA 85% recurrence vs fasciectomy 21%
• NA had faster recovery and fewer complications
• Conclusion: NA for "quick fix" with expectation of recurrence; fasciectomy for "definitive" treatment
• Both are appropriate depending on patient values and priorities

---

Q6: A patient presents with a painful palmar nodule. What is your differential diagnosis and how do you distinguish Dupuytren's from other causes?

Model Answer:

Key Point: Dupuytren's is characteristically painless in > 90% of cases (except transient tenderness during early proliferative nodule phase). Persistent pain should prompt consideration of alternative diagnoses.

Differential Diagnosis:

1. Trigger Finger (Stenosing Tenosynovitis)

   • Distinguish: Tender over A1 pulley (distal palmar crease), painful clicking/locking with active finger flexion, no palpable cord or skin pitting
   • May coexist: 10-15% of Dupuytren's patients also have trigger finger

2. Palmar Ganglion Cyst

   • Distinguish: Fluctuant, transilluminates, mobile (not fixed to skin), may communicate with joint/tendon sheath
   • Imaging: Ultrasound shows fluid-filled cyst

3. Giant Cell Tumor of Tendon Sheath (GCT-TS)

   • Distinguish: Firm, lobulated, mobile mass along flexor tendon, NOT fixed to skin
   • Imaging: MRI shows nodular mass with low T1/T2 signal
   • Definitive: Biopsy shows multinucleated giant cells

4. Inclusion Cyst/Epidermoid Cyst

   • Distinguish: Fluctuant, dome-shaped, central punctum (pore), mobile over deeper structures
   • History: Often history of penetrating injury

5. Soft Tissue Sarcoma (Rare but Important)

   • Red Flags: Rapid growth (weeks-months), size > 5cm, deep to fascia, systemic symptoms
   • Imaging: MRI shows heterogeneous mass with enhancement
   • Urgent Referral: Sarcoma center for biopsy

6. Palmar Fasciitis (Inflammatory)

   • Distinguish: Diffuse palmar tenderness, swelling, warmth; association with systemic inflammatory conditions (RA, scleroderma)
   • Labs: Inflammatory markers, autoimmune serology

Features Supporting Dupuytren's Diagnosis:

• Painless firm nodule (except transient early tenderness)
• Fixed to skin (pitting, skin puckering)
• Palpable cord extending to digit
• Ring or little finger predominantly
• Flexion contracture (late)
• Bilateral involvement (40-60%)
• Family history, Northern European ancestry
• Associated risk factors (smoking, diabetes, alcohol)

Clinical Approach:

1. History: Duration, progression, pain, trauma, systemic symptoms, family history
2. Examination: Location, mobility, skin fixation, transillumination, neurovascular status
3. Special Tests: Active finger flexion (trigger finger), palpate along flexor tendon course
4. Imaging: Only if diagnosis uncertain (ultrasound for cyst vs solid; MRI if concern for sarcoma)
5. Biopsy: If any concern for neoplasm (rapid growth, atypical features)

Management of Early Painful Dupuytren's Nodule:

• Reassurance (pain transient, settles in weeks-months)
• Activity modification
• Observation
• Consider injection of triamcinolone if pain persistent (controversial; off-label)